Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Combined With Apatinib in Advanced UPS and ASPS
NCT04447274Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Jul 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in undifferentiated pleomorphic sarcoma (UPS), alveolar soft part sarcoma (ASPS), sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
undifferentiated pleomorphic sarcoma (UPS)alveolar soft part sarcoma (ASPS)
Beyond the preview
Go deeper on NCT04447274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04447274.